DexComXSWX:DXCM 90 EV-to-FCF is 18.19 as of Jun. 26, 2026, which is 89% below its 10-year median of 158.39. GuruFocus rates XSWX:DXCM with a GF Score™ of 90/100 and a GF Value™ of CHF85.31. The stock has 3 warning signs investors should review. Among 421 Medical Devices & Instruments companies, DexCom ranks better than 62.23% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, DexCom's Enterprise Value is CHF20,691 Mil.
DexCom's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1,138 Mil. Therefore, DexCom's EV-to-FCF for today is 18.19.
The historical rank and industry rank for DexCom's EV-to-FCF or its related term are showing as below:
XSWX:DXCM'
s EV-to-FCF Range Over the Past 10 Years
Min: -2705.03 Med: 158.39 Max: 14152.97
Current: 17.81
During the past 13 years, the highest EV-to-FCF of DexCom was 14152.97. The lowest was -2705.03. And the median was 158.39.
XSWX:DXCM's EV-to-FCF is ranked better than 62.23% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 22.82
vs XSWX:DXCM: 17.81
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-26), DexCom's stock price is CHF56.54.
DexCom's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.867. Therefore, DexCom's PE Ratio (TTM) for today is 30.28.
DexCom (XSWX:DXCM) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DexCom's share price for today is CHF56.54.
DexCom's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.867.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
DexCom EV-to-FCF Related Terms
DexCom EV-to-FCF Historical Data
* Premium members only.
The historical data trend for DexCom's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, DexCom's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where DexCom's EV-to-FCF falls into.
DexCom's current Enterprise Value is CHF20,691 Mil.
DexCom's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1,138 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexCom (XSWX:DXCM) has a EV-to-FCF of 18.19 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on DexCom and its competitors. This is 89% below median its historical median of 158.39. According to the industry distribution chart, DexCom ranks #159 out of 421 companies in the Medical Devices & Instruments industry, placing it in the top 37.8%.
Is DexCom's EV-to-FCF too high?
DexCom's current EV-to-FCF of 18.19 is 89% below median its 10-year median of 158.39. The Medical Devices & Instruments industry median EV-to-FCF is 22.82. DexCom's value of 18.19 is 20.3% below this industry median. Based on the distribution chart, DexCom ranks #159 out of 421 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, DexCom has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's EV-to-FCF compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #159 out of 421 companies for EV-to-FCF. This puts DexCom in the upper half of its industry. The industry median EV-to-FCF is 22.82. DexCom's value of 18.19 is 20.3% below this benchmark. While the company's 10-year median is 158.39 vs. the industry median of 22.82, DexCom has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.82, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexCom's current EV-to-FCF of 18.19 is 20.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on DexCom and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current EV-to-FCF is 18.19, which is 89% below median its own 10-year median of 158.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current EV-to-FCF of 18.19. The stock's GF Value™ is CHF85.31, compared to a current price of CHF56.54 — trading 33.7% below its estimated fair value. The current EV-to-FCF is 18.19, which is 89% below median its 10-year median of 158.39 and 20.3% below the Medical Devices & Instruments industry median of 22.82. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current EV-to-FCF is 18.19 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (XSWX:DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of CHF56.54 is trading 33.7% below its estimated GF Value™ of CHF85.31.
Key valuation signals for XSWX:DXCM:
EV-to-FCF: 18.19 (89% below median its 10-year median of 158.39)
GF Value™: CHF85.31 vs. price of CHF56.54 (33.7% below fair value)
Industry Position: 20.3% below the Medical Devices & Instruments median (#159 of 421)
No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score
Get the complete analysis for XSWX:DXCM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DXCM has been successfully added to your 
